Clinical trial
Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell…
NCT00411086 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00411086 |
|---|---|
| Title | Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma |
| Official title | Single-Arm, Open-Label, Phase II Trial of Rituximab Plus Sargramostim for the Treatment of Newly Diagnosed Follicular B-Cell Lymphoma in Adults |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Bayer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | Rituximab, Sargramostim (GM-CSF) |
| Enrollment | 60 |
| Start date | Nov 1, 2006 |
| Primary completion | Nov 1, 2016 |
| Completion | Nov 1, 2016 |
| First posted | Dec 13, 2006 |
| Last update posted | Dec 5, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: